drugset / Trial / NCT01006603

Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin

NCT01006603

Phase 4 Completed 957 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and tolerability of saxagliptin compared to glimepiride in elderly patients with type 2 diabetes mellitus who have inadequate glycaemic control on metformin monotherapy.

Timeline

Start
2009-10
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule 1 mg Oral
Comparator Glimepiride Small molecule 2 mg Oral
Comparator Glimepiride Small molecule 3 mg Oral
Comparator Glimepiride Small molecule 4 mg Oral
Comparator Glimepiride Small molecule 6 mg Oral
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral